Stefan D. Anker
Inserm
4 papers in the Anchorcite directory, published between 2013 and 2021, cited 30,450 times in total.
ORCID profileResearch topics
- Heart Failure Treatment and Management · 3 papers
- Clinical practice guidelines implementation · 2 papers
- Cardiovascular Function and Risk Factors · 2 papers
- Diabetes Treatment and Management · 2 papers
- Blood Pressure and Hypertension Studies · 1 paper
- Cardiovascular Health and Disease Prevention · 1 paper
Frequent co-authors
- Piotr P. Ponikowski · 4 papers
- Faiez M. Zannad · 3 papers
- José Ramón González‐Juanatey · 3 papers
- Luis Miguel Ruilope · 2 papers
- Héctor Bueno · 2 papers
- Milton Packer · 2 papers
- Javed Butler · 2 papers
- Gerasimos S Filippatos · 2 papers
Papers
- 2013 ESH/ESC Guidelines for the management of arterial hypertensionEuropean Heart Journal · 2013 · 13,739 citations
The ESH/ESC Guidelines represent the views of the ESH and ESC and were arrived at after careful consideration of the available evidence at the time they were written.Health professionals are encouraged to take them fully into account when exercising their…
- 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart FailureEuropean Journal of Heart Failure · 2016 · 6,032 citations
... Guidelines summarize and evaluate all available evidence on a particular issue at the time of the writing process, with the aim of assisting health professionals in selecting the best management strategies for an individual patient with a given condition,…
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart FailureNew England Journal of Medicine · 2020 · 5,468 citations
BACKGROUNDSodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless of the presence or absence of diabetes.More evidence is needed regarding the effects of these drugs in patients across the broad spectrum of heart…
- Empagliflozin in Heart Failure with a Preserved Ejection FractionNew England Journal of Medicine · 2021 · 5,211 citations
BACKGROUND: Sodium-glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, but their effects in patients with heart failure and a preserved ejection fraction are uncertain. METHODS: In…
Metadata from OpenAlex (CC0).